SomaLogic stock trades at USD 2.10 after business sale

SomaLogic stock trades at USD 2.10 in a market snapshot dated September 20, 2026, giving the company a market capitalization of USD 396.23 million. The quote sits 44.6 percent below its 52-week high of USD 3.79, a gap that frames the stock around the ownership change involving its operating business.

Business ownership changed in 2026

Stock Titan reports that Standard BioTools completed the sale of the SomaLogic entities to Illumina on January 30, 2026. The transaction covered the SomaScan business, including its assay platform and related products and services.

The sale changes how the name should be read in the market. SomaLogic's former operating assets now belong to Illumina, while the quoted SLGC security remains tied to the public-company history captured by the market snapshot.

Valuation stays below yearly peak

At USD 2.10, the stock stands USD 1.69 below the USD 3.79 52-week high and USD 0.37 above the USD 1.73 low. That spread places the quote 21.4 percent above the yearly low, creating a wider valuation picture than the headline price alone.

The market capitalization of USD 396.23 million is more than a price statistic. It measures the equity value assigned to a listed name whose core SomaScan business changed ownership during 2026, so corporate structure is as important as operating growth in interpreting the quote.

Stock trades at USD 2.10

SomaLogic stock trades at USD 2.10 as of September 20, 2026. The 52-week range of USD 1.73 to USD 3.79 shows that the quote is materially closer to the low than the high, while the January 30, 2026 sale gives the listing a distinct corporate-history backdrop.